Former Benchmark genetics Chile CEO Dr Matias del Campo is now in charge of Vaxxinova Norway and Chile. Photo: Vaxxinova.

Vaccine developer names new fish division boss

A former PhD student at Stirling University’s Institute of Aquaculture has been named managing director of Vaxxinova Norway and Vaxxinova Chile, which are focused on producing vaccines targeting the major disease challenges in cold-water species.

Published Last updated

Dr Matias del Campo has an aquaculture engineering degree from the University Andres Bello in Chile and a PhD in aquaculture from Stirling.

He has 20 years’ experience in aquaculture and has held several senior management positions in Chilean and international science and technology companies. Del Campo was chief executive for Aquainnovo and ATC Patagonia (2013-2018), a role which evolved into chief executive for Benchmark Genetics Chile from 2018 until last month.

Preventative solutions

Vaxxinova Norway is dedicated to providing solutions for the major challenges on the Norwegian market but will also extend its scope of activity to provide effective biological preventive solutions to the aquaculture industry in Europe, Canada and Chile, parent company Vaxxinova International said in a press release.

Vaxxinova International is part of German agribusiness giant EW Group, which also owns salmon egg producer AquaGen and GenoMar Genetics, the world’s largest tilapia breeding company.